Posted by Michael Wonder on 16 Aug 2016
Amgen, Sanofi cholesterol drugs not cost-effective, study says
17 August 2016 - Medicines would need prices cut by two-thirds: researchers.
Amgen, Sanofi and Regeneron Pharmaceuticals would need to cut prices on their new cholesterol-lowering drugs by more than two-thirds to make them cost-effective to use in the U.S., a study found.
The high list prices of the injectable medicines Praluent and Repatha -- which on average cost more than $14,000 per patient each year in the U.S. -- is “uniquely challenging” because they are meant to be lifelong treatments for a growing number of people, according to the study, published Tuesday in the Journal of the American Medical Association.
